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Abstract
FLT3 is a type III receptor tyrosine kinase. Mutations of FLT3 comprise one of the most frequently identified types
of genetic alterations in acute myeloid leukemia. One-third of acute myeloid leukemia patients have mutations of
this gene, and the majority of these mutations involve an internal tandem duplication in the juxtamembrane
region of FLT3, leading to constitutive activation of downstream signaling pathways and aberrant cell growth. This
review summarizes the current understanding of the effects of the downstream molecular signaling pathways after
FLT3 activation, with a particular focus on the effects on transcription factors. Moreover, this review describes novel
FLT3-targeted therapies, as well as efficient combination therapies for FLT3-mutated leukemia cells.
Introduction
FLT3 (Fms-like tyrosine kinase 3) is a member of the
class III receptor tyrosine kinase family. Notably,
approximately one-third of acute myeloid leukemia
(AML) patients have mutations of this gene, and such
mutations are one of the most frequently identified
types of genetic alterations in AML. The majority of the
mutations involve an internal tandem duplication (ITD)
in the juxtamembrane (JM) domain of FLT3, which is
specifically found in AML [1]. In accordance with the
two-hit hypothesis [2] of leukemic transformation,
FLT3-ITD expression in mouse bone marrow cells
expressing a promyelocytic leukemia (PML)/retinoic
acid receptor (RAR) a fusion protein of acute promyelo-
cytic leukemia (APL) caused accelerated malignant
transformation [3]. Indeed, FLT3-ITD is prevalent
(~50%) in patients with translocations of t(15;17) [4]. In
addition, frequent co-occurrence of mutations of FLT3
with mutations of nucleophosmin (NPM) [5] and DNA
methyltransferase 3A [6] were reported in AML patients
with normal karyotypes. These observations suggest that
FLT3 mutations functionally cooperate with other mole-
cules for leukemic transformation.
Based on these data and the literature, this review
summarizes the current understanding of the preva-
lence, correlation with other molecular alterations, and
intracellular downstream signaling pathways of FLT3
mutations. Moreover, the oncogenic effects of FLT3
mutations on myeloid transcription factors are also dis-
cussed. Furthermore, this review describes efficient com-
bined molecularly-targeted therapeutic approaches for
FLT3-activated AML cells.
FLT3 structure and FLT3 ligand
The structure of FLT3 is shown in Figure 1. Two dis-
tinct classes of mutations have been identified in
patients with AML, and the most common is an ITD in
the JM region of the receptor [1]. Even though the ITD
insertions vary in length, they always maintain a head-
to-tail orientation and preserve the reading frame. It has
been suggested that a conformational change in the JM
domain is responsible for dimerization and receptor
activation [7]. The second most common type of FLT3
mutations in AML are mutations in the activation loop
of the tyrosine kinase domain (TKD) (Figure 1). Almost
all of these mutations involve an aspartate-to-tyrosine
substitution at codon 835, although other substitutions
have also been identified [8,9]. These mutations cause a
conformational change of the molecule and disrupt its
autoinhibitory function, thereby rendering the receptor
constitutively active [2,10,11].
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13q12 and encompasses 24 exons. It encodes a mem-
brane-bound glycosylated protein of 993 amino acids
with a molecular weight of 158-160 kDa, as well as a
non-glycosylated isoform of 130-143 kDa that is not
associated with the plasma membrane [10,12]. After the
cloning of the Flt3 gene, soluble mouse Flt3 was used
to clone the gene encoding the mouse Flt3 ligand (FL)
[13]. The mouse FL cDNA was then used to clone the
human FL gene [14]. The mouse and human FL genes
encode proteins of 231 and 235 amino acids, respec-
tively [15]. The cytoplasmic domains of murine and
human FL show only 52% identity in the cytoplasmic
domain. The FL gene encodes a type 1 transmembrane
protein that contains an amino-terminal signaling pep-
tide, four extracellular helical domains, spacer and
tether regions, a transmembrane domain and a small
cytoplasmic domain [15]. FL is expressed by most tis-
sues, including hematopoietic organs (spleen, thymus,
peripheral blood and bone marrow) and the prostate,
ovary, kidney, lung, colon, small intestine, testis, heart
and placenta, with the highest level of expression in
peripheral blood mononuclear cells [11]. The brain is
one of the few tissues without demonstrable expression
of FL. Most immortalized hematopoietic cell lines
express FL [11,16].
The expression of FL by a wide variety of tissues is in
contrast to the limited expression pattern of FLT3,
which is mainly found in early hematopoietic progenitor
cells. These observations indicate that the expression of
FLT3 is a rate-limiting step in determining the tissue-
specificity of FLT3 signaling pathways.
FLT3 mutations in hematopoietic malignancies
In 1996, Nakao et al. [17] found a unique mutation of
FLT3 in AML cells. This mutation, comprising an ITD
in the JM domain of the receptor (Figure 1), caused the
coding sequence to be duplicated and inserted in a
direct head-to-tail succession [17]. Subsequent studies
showed that ITD mutations of the FLT3 gene occur in
approximately 24% of adult AML patients [2]. In
addition, activating point mutations of the FLT3 TKD,
mainly at aspartic acid 835 (Figure 1), are found in
approximately 7% of AML patients [9].
Since the first description, numerous studies have
confirmed and extended these findings to the extent
that FLT3 mutations are currently the most frequent
single mutations identified in AML, and approximately
one-third of AML patients have mutations of this gene
[1,18]. FLT3-ITD mutations have also been detected in
3% of patients with myelodysplastic syndromes [1], and
occasional patients with acute lymphoid leukemia
[19,20] and chronic myeloid leukemia [21]. They have
not been found in patients with chronic lymphoid leu-
kemia, non-Hodgkin’s lymphoma or multiple myeloma
[1], or in normal individuals [22,23]. These findings
suggest that FLT3 mutations have strong disease speci-
ficity for AML.
As a general rule, the presence of an ITD in adult
patients seems to have little or no impact on the ability
to achieve complete remission (CR). In children, how-
ever, several studies have reported a reduced CR rate
[7,24]. The most significant impact of an ITD is its asso-
ciation with a higher leukocyte count, increased relapse
risk (RR), decreased disease-free survival (DFS) and
decreased overall survival (OS), which have been
reported in most studies of children and adults aged less
than 60 years [23]. Several groups found that an ITD is
the most significant factor for predicting an adverse out-
come in multivariate analyses [7,23,25,26]. In contrast,
FLT3-TKD mutations tend to worsen the DFS and OS
[9], although the differences are statistically significant
for OS in patients aged less than 60 years [27]. In addi-
tion, it was reported that even in patients with normal
cytogenetics and wild-type FLT3 (n = 113), clear ten-
dencies for worse OS and event-free survival were found
in patients with high FLT3 expression (n = 43) [28].
Falini et al. [5] described abnormal localization of
NPM1 in AML patients. The C-terminus of this protein
is mutated in approximately 27.5% of AML patients
[29], and such mutations are probably the second most
prevalent type of mutations in AML patients. A subse-
quent study suggested that NPM1 mutations are
strongly associated with FLT3-ITD mutations in patients
with a normal karyotype (NPM1-mutant/FLT3-ITD:
43.8% versus NPM1-wild-type/FLT3-ITD: 19.9%; P <
0.001) [29]. Quite recently, it was reported that Dnmt3A
mutations were detected in 62 of 281 AML patients
(22.1%), and these mutations were highly enriched in a
group of patients with an intermediate-risk cytogenetic
profile as well as FLT3 mutations (25 of 61 patients,
41.0%; P < 0.003) [6].
AML is a multistep process that requires the colla-
boration of at least two classes of mutations, comprising
class I mutations that activate signal transduction
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Figure 1 Schematic presentation of the FLT3 receptor.
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topoietic cells and class II mutations that affect tran-
scription factors and primarily serve to impair
hematopoietic differentiation [30,31] (Table 1). Hou et
al. [32] investigated the prevalence and clinical relevance
of mutations of PTPN11, which encodes human SHP2,
and their associations with other genetic changes in 272
consecutive patients with primary AML. Among 14
patients with PTPN11 mutations, none had FLT3-ITD
mutations. On the other hand, 6 of 14 patients with
PTPN11 mutations had concurrent NPM1 mutations
[32], suggesting PTPN11 is classified as a class I muta-
tion molecule similar to the case for FLT3.
FLT3-ITD mutations are correlated with certain cytoge-
netic subgroups. Among APL patients with PML-RARa,i t
was reported that 30-50% of the patients had FLT3 muta-
tions [4,27,33]. Frequent (~90%) co-occurrence was
reported in patients with t(6; 9) and FLT3-ITD mutations
[27,34]. Similarly, FLT3-ITD mutations are also frequently
found in patients with mixed lineage leukemia (MLL)-par-
tial tandem duplication (PTD) [35]. The rate of MLL-PTD
in FLT3-ITD-positive patients was significantly higher than
that in FLT3-ITD-negative patients [16/184 (8.7%) versus
32/772 (4.1%); P = 0.025] [35]. In analyses involving 353
adult de novo AML patients, Carnicer et al. [36] found
cooperative mutations of FLT3-TKD with CBFb/MYH11
rearrangement (four of 15 patients) and C/EBPa with
FLT3-ITD (two of 82 patients). In comprehensive analyses
of 144 newly diagnosed de novo AML patients, Ishikawa et
al. [37] also found that most overlapping mutations consist
of class I and class II mutations (Table 1). In addition to
the frequent co-occurrence of FLT3 mutations with muta-
tions of other molecules (e.g. NPM1, MLL-PTD, CBFb/
MYH11 rearrangement), they found that two of the 35
patients with FLT3 mutations also had AML1/ETO. Col-
lectively, FLT3-ITD mutations play a key role in leukemo-
genesis by functionally cooperating with other molecules.
Downstream pathways of normal FLT3
FL-mediated triggering of FLT3 induces receptor autop-
hosphorylation at tyrosine residues, thereby creating
docking sites for signal-transducing effector molecules
and activating various signaling pathways. The down-
stream signaling cascade involves the tyrosine phosphor-
ylation and activation of multiple cytoplasmic molecules.
The FLT3 cytoplasmic domain physically associates with
the p85 subunit of phosphoinositol-3-kinase (PI3K), Ras
GTPase, phospholipase C-g, Shc, growth factor receptor-
bound protein (Grb2) and Srcf a m i l yt y r o s i n ek i n a s e ,
and results in the phosphorylation of these proteins
[38]. These actions affect the activation of further down-
stream PI3K/protein kinase B (Akt) and mitogen-
activated protein kinase (MAPK) pathways [39,40].
Bruserud et al. [41] reported that exogenous FL
increases blast proliferation for not only patients with
wild-type FLT3 but also patients with FLT3-ITD, as well
as, FLT3-TKD mutations. Therefore, FL-mediated
triggering of FLT3 appears to be important for both
wild-type and mutant FLT3 signaling.
Downstream pathways of oncogenic FLT3
FLT3-ITD mutations, as well as TKD mutations, result
in the constitutive activation of FLT3 kinase. Mutations
in the FLT3 JM domain and activation loop can be pre-
dicted to result in loss of the autoinhibitory function,
with subsequent constitutive activation of FLT3 kinase
and its downstream proliferative signaling pathways,
including the Ras/MAPK kinase (MEK)/extracellular sig-
nal-regulated kinase (ERK) pathway and PI3K/Akt path-
way [2]. In addition, and in contrast to wild-type FLT3
signaling, FLT3-ITD potently activates the STAT5 path-
way [42-44]. STAT5 induces its target genes such as
cyclin D1, c-myc and the anti-apoptotic gene p21, which
are important for cell growth [45,46]. These effects may
indicate a role of FLT3-ITD in the aberrant cell growth
of leukemia cells [40,47]. In a microarray study using
FLT3-ITD-expressing transgenic 32Dcl cells, the STAT5
target gene of a serine threonine kinase, Pim-2, was
induced [43]. A different group reported that another
serine threonine kinase, Pim-1, was upregulated by
FLT3-ITD and is important for FLT3-ITD-mediated cell
growth and anti-apoptotic effects [48]. Taken together,
FLT3-ITD constitutively induces STAT5 and Pim serine
threonine kinases, and their mechanisms may accelerate
AML cell growth.
Sallmyr et al. [49] reported that FLT3-ITD mutations
start a cycle of genomic instability whereby increased
reactive oxygen species (ROS) production leads to
increased DNA double-strand breaks (DSBs) and repair
errors. They found that FLT3-ITD-transfected cell lines
and FLT3-ITD-positive AML cell lines and primary cells
exhibit increased ROS production. The increased ROS
levels appear to be produced via STAT5 signaling and
activation of RAC1, an essential component of ROS-pro-
ducing NADPH oxidases. They provided a possible
Table 1 A list of class I, class II and unclassified
mutations
Class I mutations: Providing
cellular proliferative and/or
survival advantage
Class II mutations:
Impairing cellular
differentiation
Unclassified
mutations:
Flt3 mutation PML-RARa NPM1
c-KIT mutation AML1-ETO Dnmt3a
N-or K-Ras mutation CBFb-MYH11
PTPN11 AML1 mutation
C/EBPa mutation
MLL-PTD
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a direct association of RAC1-GTP binding to phos-
phorylated STAT5 (pSTAT5), and inhibition of the
pSTAT5 level resulted in the decrease of ROS produc-
tion. They concluded that the aggressiveness of the dis-
ease and the poor prognosis of AML patients with
FLT3-ITD mutations could be the result of increased
genomic instability driven by higher endogenous ROS,
increased DNA damage and decreased end-joining fide-
lity. Further analyses from the same research group
using FLT3-ITD-expressing cell lines and bone marrow
mononuclear cells from FLT3-ITD knock-in mice
demonstrated that the end-joining of DSBs occurs at
microhomologous sequences, resulting in a high fre-
quency of DNA deletions [50]. They found that the
levels of Ku proteins, which are key components of the
main nonhomologous end-joining (NHEJ) pathway, are
decreased in FLT3-ITD cells. Concomitantly, the levels
of DNA ligase IIIa, a component of alternative and less
well-defined backup end-joining pathways, are increased
in FLT3-ITD cells [50]. Cells treated with an FLT3 inhi-
bitor exhibit decreased DNA ligase IIIa expression and
a reduction in DNA deletions, suggesting that FLT3 sig-
naling regulates the pathways by which DSBs are
repaired [50]. Therefore, therapies to inhibit FLT-ITD
signaling and/or DNA ligase IIIa expression may lead to
repair that reduces repair errors and genomic instability.
It is notable that more than two-thirds of AML
patients show FLT3 phosphorylation, even in the
absence of activating mutations [51,52]. Increased FLT3
transcript levels are observed in a large number of AML
samples, and this increased expression may also contri-
bute to the phosphorylation of FLT3 and activation of
its pathways [52]. Since several receptor tyrosine kinases
are dimerized and activated even without ligand binding
to their receptors [53], the upregulation of FLT3 may
facilitate its dimerization and thereby enhance the phos-
phorylation. Meanwhile, Zeng et al. [51] demonstrated
an increase in FLT3 autophosphorylation when leukemic
blasts were incubated in medium for a while after being
thawed, compared with washed newly thawed blast cells.
Their findings indicate that the secreted soluble form of
FL plays a role in cells with constitutive activation of
wild-type FLT3.
Inhibition of transcription factor functions by FLT3-ITD
Scheijen et al. [54] reported that FLT3-ITD expression
in Ba/F3 cells resulted in activation of Akt and concomi-
tant phosphorylation of the Forkhead family member
FOXO3a. Phosphorylation of FOXO3a threonine 32
through FLT3-ITD signaling promotes their transloca-
tion from the nucleus to the cytoplasm. Specifically,
FLT3-ITD expression prevented FOXO3a-mediated
apoptosis and upregulation of p27KIP1 and Bim gene
expression, suggesting that the oncogenic tyrosine
kinase FLT3 can negatively regulate FOXO transcription
factors through the phosphorylation of FOXO3a leading
to suppression of its function, thereby promoting the
survival and proliferation of AML cells [54].
FLT3-ITD is also known to inhibit the expression
and function of several myeloid transcription factors.
FLT3-ITD specifically inhibits the expression [55] as
well as the function of C/EBPa through phosphoryla-
tion of the N-terminal serine 21 of this protein by acti-
vation of ERK [56]. Following this aberrant
phosphorylation of C/EBPa, the differentiation of
FLT3-ITD cells is blocked [56]. It was reported that
mice carrying hypomorphic PU.1 alleles, which reduce
PU.1 expression to 20% of the normal level, developed
AML [57]. The expression of PU.1 is also significantly
suppressed by FLT3-ITD [43,55]. In addition, the
author’s group previously reported that high expression
of FLT3 is associated with low expression of PU.1 in
primary AML cells [58]. These observations indicate
that blockade of the function of myeloid transcription
factors by FLT3 oncogenic signaling plays an impor-
tant role in the pathogenesis of AML.
Silencing mediator of retinoic acid and thyroid hor-
mone receptors (SMRT) recruits histone deacetylase
(HDAC) and mediates transcriptional repression by
interacting with various transcriptional repressors,
including AML1-ETO [59], Runx1/AML1 [60] and pro-
myelocytic leukemia zinc finger (PLZF) [47]. PLZF was
identified as the translocation partner of RARa in t
(11;17)(q23;q21) retinoid-resistant APL [61]. PLZF is
expressed in myeloid progenitor cells and downregu-
lated as the cells differentiate [61-63], suggesting an
important role of PLZF in normal myeloid cell develop-
ment. PLZF is a transcriptional repressor and a potent
growth suppressor that blocks cell proliferation and
myeloid differentiation through silencing of its target
genes, including cell cycle regulators such as cyclin A2
[64,65]. The author and colleagues previously reported
that FLT3-ITD expression dissociates PLZF and SMRT,
and inhibits the function of PLZF, leading to aberrant
gene regulation and abnormal cell growth in leukemia
[47]. Runx1/AML1 is a Runt family transcription factor
that is critical for normal hematopoiesis and regulates
various genes as either a transcriptional activator or
repressor [66]. Recently, it was reported that Runx1/
AML1 functions as a senescence inducer [67]. Intrigu-
ingly, the author’s group revealed that the Runx1/
AML1-SMRT interaction is also disrupted by FLT3-
ITD, leading to disruption of the function of Runx1/
AML1 and aberrant expression of the Runx1/AML1 tar-
get gene p21
WAF1/CIP1 [60]. These findings are quite
consistent with the notion of Yan et al. [68], who
reported that disruption of the interaction between
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genic potential of AML1-ETO. These findings are sum-
marized in Table 2 and Figure 2. These observations
indicate that inhibition of transcriptional repressor,
growth repressor and senescence inducer functions
through the dissociation of transcriptional repressors
and co-repressors by aberrant FLT3-ITD signaling may
another crucial mechanism for leukemogenesis.
FLT3-targeted therapies
The clinical outcome of AML was dramatically
improved by the development of effective chemotherapy
in the 1970s and subsequently improved by the develop-
ment of hematopoietic stem cell transplantation therapy
in the 1980s. However, the clinical outcome of AML has
not improved since the 1990s, with the exception of the
identification of all-trans-retinoic acid therapy for APL.
Currently, highly specific molecularly-targeted therapies
for AML cells are being investigated to further improve
the clinical outcome of AML.
Since the identification of the high frequency of FLT3
mutations in AML, approximately 20 different experi-
mental and/or clinical FLT3 inhibitors have been devel-
oped and described in the literature [69-82]. The
compounds currently in development are heterocyclic
compounds containing components that structurally
mimic the purine ring of adenosine and become inserted
into the ATP-binding site of FLT3 [69]. Among these
compounds, SU11248 (sunitinib), MLN518 (tandutinib),
CEP-701 (lestaurtinib) and PKC412 (midostaurin) have
passed through preclinical studies and made the bench-
to-bedside transition to clinical trials [69,82]. Although
these inhibitors appear to have some activity as single
agents, the responses to date have tended to be incom-
plete or of limited duration [83-86]. AC220 is a second-
generation FLT3 inhibitor that appears to have excellent
potency and selectivity for target inhibition in vivo [87].
Lestaurtinib trials have included extensive pharmacody-
namic studies, and the data suggest that such first-gen-
eration FLT3 inhibitors inhibit their target in some but
not all patients [82]. Although not definitive, such stu-
dies suggest the possibility that FLT3 inhibitors may
have only a limited role as single-agent therapies, at
least in patients with refractory or repeatedly relapsing
AML. Although some patients with FLT3-ITD muta-
tions can respond if adequate drug levels are achieved, a
large number of patients are potentially resistant to the
administration of single FLT3 inhibitors. These observa-
tions imply the presence of mechanisms by which leuke-
mic blasts can evade the effects of FLT3 inhibitors [88].
The acquisition of secondary tyrosine kinase domain
point mutations that interfere with drug binding is a
well-documented phenomenon in CML patients receiv-
ing therapy with imatinib [89]. Preclinical studies using
AML cell lines have shown that small variations in the
molecular structure of the FLT3 activation loop can
greatly influence the response to FLT3 inhibitors. Cells
that express different FLT3-TKD mutations show dis-
tinctly different profiles of in vitro drug responses [90].
Cools et al. [91] described the results of an in vitro
screen designed to discover mutations in the ATP-bind-
ing pocket of FLT3 that cause drug resistance, in which
point mutations at four different positions were identi-
fied. These mutations conferred varying degrees of resis-
tance to PKC412, with variable cross-reactivity observed
for other inhibitors. Heidel et al. [92] reported the
acquisition of a secondary FLT3-TKD mutation in a
patient who responded to PKC412 but became resistant
to the drug after 280 days of treatment. This patient
was found to have developed a point mutation at one of
the positions identified by Cools et al. [91], which had
not been present at diagnosis. Research using FLT3
inhibitor-resistant leukemia cell lines generated through
prolonged cocultures with FLT3 inhibitors has revealed
that FLT3 inhibitor-resistant cells most frequently
become FLT3 independent because of the activation of
parallel signaling pathways that provide compensatory
survival/proliferation signals when FLT3 is inhibited
[93]. In resistant cells, FLT3 itself can still be inhibited
but several signaling pathways normally switched off by
Table 2 Inhibition of transcription factor functions by FLT3-ITD
Author Target Responsible signaling pathway Mechanisms of the action
Mizuki et al. [43] C/EBPa, PU.1 unknown Down-regulates myeloid transcription factor C/EBPa and PU.1 expression.
Scheijen et al. [54] FOXO3a Akt Inhibition of FOXO3a leads to the upregulation of p27KIP1 and Bim gene
expression. These promote cell survival and proliferation.
Zheng et al. [55] C/EBPa, PU.1 unknown Down-regulates myeloid transcription factor C/EBPa and PU.1 expression.
Those may play a role in myeloid differentiation block.
Radomska et al. [56] C/EBPa MEK/ERK Phosphorylates serine 21 of C/EBPa, results in the differentiation block of
MV4;11 cells.
Takahashi et al. [47] PLZF MEK/ERK Dissociates its transcriptional co-repressor SMRT, inhibits the growth
suppressor function of PLZF, leading to abnormal cell growth.
Takahashi et al. [60] Runx1/AML1 unknown Runx1/AML1-SMRT interaction is disrupted by FLT3-ITD, leading to the
aberrant expression of the Runx1/AML1target gene p21
WAF1/CIP1.
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MAPK pathways, remain activated. Newly acquired acti-
vating NRAS mutations were found in two of the resis-
tant cell lines, suggesting another means by which
resistance may be acquired [93]. In addition, AML is a
complex multigenetic disease and the simultaneous inhi-
bition of other important tyrosine kinases, scaffolding
proteins or relatively broad cytotoxic agents may be
therapeutically advantageous as described in the next
section.
Development of efficient combination therapies for FLT3
mutated cells
In this context, several groups have recently reported
that combinations of FLT3 inhibitor therapy and che-
motherapy are synergistically effective [94-96]. Both
CEP-701 and SU11248 have been investigated in combi-
nation with chemotherapy using in vitro models [94,95].
CEP-701 was found to induce cytotoxicity in a synergis-
tic fashion with cytarabine, daunorubicin, mitoxantrone
or etoposide when administered simultaneously with or
immediately after the chemotherapeutic agent [94].
Additive or synergistic cytotoxic effects were also seen
when model cell lines and primary blasts expressing
FLT3-ITD mutants were simultaneously treated with
SU11248 and daunorubicin or cytarabine [95].
The MEK/MAPK pathway is an important signaling
cascade involved in the control of hematopoietic cell pro-
liferation and differentiation [97,98]. Downregulation of
MEK phosphorylation inhibits proliferation and induces
apoptosis of primary AML blasts [99]. Consistent with
these effects, the author found that inhibition of MEK/
MAPK signal transduction strongly impairs the growth
of FLT3-ITD cells [39]. Radomska et al. [56] recently
reported the importance of inhibition of this pathway for
not only cell growth but also restoration of the FLT3-
ITD-mediated differentiation blockade of cells. These
findings suggest that MEK is probably a good target for
combination therapies with FLT3 inhibitors. Arsenic tri-
oxide (ATO) has shown great promise in the treatment
of patients with relapsing or refractory APL. It was
recently reported that the combination of ATO with a
MEK inhibitor is very efficient for not only APL blasts
but also AML patients [100]. The author’sg r o u p
reported synergistic effects of ATO and MEK inhibition,
as well as ATO and FLT3 inhibition, on FLT3-ITD cells
[101]. The combination of ATO and AG1296, an FLT3
inhibitor, profoundly inhibited the growth and induced
apoptosis of FLT3-ITD cells [101]. Common chemother-
apeutic drugs usually haveaw i d er a n g eo fc y t o t o x i c
effects on hematopoietic stem cells or progenitor cells of
other tissues. In addition, there are many serious side
effects of chemotherapy [102]. In contrast, the therapeu-
tic dose of ATO used to treat APL is associated with an
acceptable toxicity level without bone marrow hypoplasia
or alopecia [103]. From these points of view, combination
t h e r a p yw i t hA T Om a yb ea d v a n t a g e o u sf o rn o to n l y
APL but also non-APL hematologic malignancies [104].
FLT3 has been shown to be a client protein for a cha-
perone, heat shock protein (Hsp) 90 [105]. Treatment
with an Hsp90 inhibitor, such as herbimycin A, radicicol
or 17-allylamino-demethoxy geldanamycin (17-AAG),
was found to disrupt the chaperone association of FLT3
with Hsp90, thus directing FLT3 toward polyubiquitina-
tion and proteasomal degradation [106]. Hsp90 is likely
to target misfolded proteins generated by mutations. It
i st h e r e f o r ep o s s i b l et h a tF L T 3 - I T Dp r o t e i n sa r e
unstable and require chaperoning by Hsp90 in leukemic
cells. Consequently, combination therapy with an FLT3
inhibitor and an Hsp90 inhibitor, 17-AAG, was found to
be effective against FLT3-ITD leukemia cells [107,108].
Chemokine stromal-derived factor 1a and its cognate
receptor C-X-C chemokine receptor type 4 (CXCR4)
were shown to act as critical mediators in stromal-leuke-
mic cell interactions. CXCR4 is involved in the migration,
homing and engraftment of AML cells to the bone mar-
row of NOD/SCID mice [109,110]. Intriguingly, CXCR4
expression was found to be significantly higher in FLT3-
ITD AML samples than in FLT3-wild-type AML samples
[111]. Targeting of CXCR4 may disrupt AML-niche
interactions, sensitize leukemic blasts to chemotherapy
and overcome cell adhesion-mediated drug resistance.
Indeed, blockade of CXCR4 using small molecule inhibi-
tors caused mobilization of resistant bone marrow leuke-
mic blasts and was synergistic with conventional
chemotherapeutics [112-114]. Therefore, targeting of
CXCR4 in combination with FLT3 inhibitors may selec-
tively eradicate FLT3-ITD cells. The development of
Figure 2 Mechanisms of FLT3-ITD induced leukemogenesis.
Depicted is an outline of known pathways downstream of FLT3-ITD.
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vation may be the next breakthrough for AML therapy.
Conclusions
Considerable progress has been made in our under-
standing of the molecular pathogenesis of AML, and
numerous genetic abnormalities in AML have been
identified. FLT3 is one of the key molecules with a role
in the pathogenesis in AML. During the past decade,
the function of the FLT3 pathway has been well charac-
terized, and several FLT3 inhibitors have been devel-
oped. Nevertheless, the results of clinical trials of FLT3
inhibitors have only been partial and further precise stu-
dies for the FLT3 downstream pathways are required.
Such analyses will hopefully lead to the development of
effective therapies for AML in the future.
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